Peter Friedmann to Cost-Benefit Analysis
This is a "connection" page, showing publications Peter Friedmann has written about Cost-Benefit Analysis.
Connection Strength
0.123
-
Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction. 2017 Aug; 112(8):1440-1450.
Score: 0.123